[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_103":104,"_105":57},"item-original",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":16,"_18":-5,"_19":-5,"_20":21,"_22":23,"_24":25,"_26":27,"_28":25,"_29":30,"_31":32,"_33":34,"_35":36,"_37":38,"_39":-5,"_38":40,"_41":-5,"_42":-5,"_43":-5,"_44":45,"_46":47,"_48":-5,"_49":50,"_51":52,"_53":54,"_55":36,"_56":57,"_58":-5,"_59":60,"_61":62,"_63":36,"_64":57,"_65":66},"id","o22fsoidwwp6jqucndqvixbxp","revision",1,"title","🚨 #ESMO26 | Post-IO NSCLC","originalTitle","summary","reason","source",{"_11":97,"_76":98,"_99":100,"_101":36,"_102":-5},"links",{"_94":95,"_66":96},"publishedAt","2026-10-25T07:49:33.000Z","discoveredAt","2026-10-25T07:53:12.982Z","timelineAt","category","opinion","tags",[],"score",70,"selected",false,"channel","x","story",{"_85":86,"_87":47,"_88":-5,"_89":-5,"_90":91,"_92":93},"insight","digest","conferenceAbstracts","readingMode","full","author","OncologyMarwarD","language","body",{"_80":-5,"_66":81,"_82":83,"_84":57},"outline",[],"relatedStories",[],"indexable","markdownAvailable",true,"group","conference",{"_74":75,"_76":77,"_78":-5,"_79":-5},"engagement",{"_67":68,"_69":68,"_70":68,"_71":68,"_72":73},"posterIsAuthor","hasTranslation","bodyLanguage","original","heat",0,"likes","replies","reposts","views",3,"slug","esmo-2026","name","ESMO 2026","topic","reading","zh","

🚨 #ESMO26 | Post-IO NSCLC

🔹 Pumitamig + docetaxel: ORR 36.7%, mPFS 6.9 mo (Phase II).

🔹 CS2009 + docetaxel: ORR 55.6%, DCR 100% (n=18).

Promising dual/triple immune-angiogenic targeting strategies! ⚠️ Small, nonrandomized cohorts; no head-to-head comparison.

#LungCancer

","zhKind","translation","complete","authorName","OsmanKostekMD","handle","avatarUrl","quoted","thread",[],"media",[],"aihot","/items/o22fsoidwwp6jqucndqvixbxp","https://x.com/OncologyMarwarD/status/2114263076639756485","esmo26-floor","ESMO 2026 现场信号","kind","x_search","firstParty","iconUrl","changelogVersion","2026-10-24T20:30","enEditionEnabled"]